Hinge Health had its Relative Strength (RS) Rating upgraded from 88 to 95 Thursday.
Here Are 3 Keys For Successful Stock Investing
IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 at the beginning of a new climb.
The IBD 50 stock is now considered extended and out of buy range after clearing a 43.80 buy point in a first-stage ipo base. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth in the latest quarterly report, while sales growth came in at 55%.
The company holds the No. 10 rank among its peers in the Medical-Products industry group. TransMedics Group, ResMed and Boston Scientific are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
